title: Nivolumab for treating non-small cell lung cancer.
abstract: BACKGROUND
  Diversion of the immune checkpoint PD-1/PD-L1 by a tumor in order to escape antitumor immunity is a hallmark of NSCLC, but offers promising new strategies. Nivolumab, a fully human monoclonal antibody, is the first PD-1 inhibitor to be approved to treat metastatic NSCLC after exciting results obtained from clinical trials.
  
  
  METHODS
  This review aims to:) clarify the mechanism of action and toxicities of PD-1 inhibitors; recapitulate the results from various clinical trials that have evaluated nivolumab as a monotherapy for metastatic NSCLC; discuss the clinical and translational research axes to better use this molecule; and summarize the therapeutic combinations currently under evaluation.
  
  
  CONCLUSIONS
  The contribution of this molecule to treat NSCLC is undeniable, making it a new standard of care after prior chemotherapy. Its toxicity profile is favorable but a good knowledge of new and potentially severe immune-related adverse effects such as endocrinopathy or interstitial pneumonitis is essential for its early detection and management. Better selection of patients is needed, particularly based on the discovery of predictive biomarkers, such as PD-L1 expression. Multiple associations with other checkpoint inhibitors, chemotherapy and targeted therapies are currently being studied and should pave the way toward new uses for this drug.
authors.affiliation: a Centre Hospitalier Universitaire, Thoracic Oncology Unit, Respiratory Disease Department , Hôpital Larrey, Université Paul Sabatier , CHU Toulouse, Chemin de Pouvourville, Toulouse , Toulouse Cedex 31059 , France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Guibert
authors.affiliation: a Centre Hospitalier Universitaire, Thoracic Oncology Unit, Respiratory Disease Department , Hôpital Larrey, Université Paul Sabatier , CHU Toulouse, Chemin de Pouvourville, Toulouse , Toulouse Cedex 31059 , France.|b Hôpital Larrey , Institut Universitaire du Cancer , Toulouse , Toulouse Cedex 31059 , France.
authors.forename: Julien
authors.initials: J
authors.lastname: Mazières
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors / Q000276:immunology; D015415:Biomarkers; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; D015415:Biomarkers; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab
keywords: PD-1; PD-1 inhibitor; PD-L1; antitumor immunotherapy; immune checkpoint inhibitors; nivolumab